These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 9696790)

  • 1. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.
    Cecilia D; KewalRamani VN; O'Leary J; Volsky B; Nyambi P; Burda S; Xu S; Littman DR; Zolla-Pazner S
    J Virol; 1998 Sep; 72(9):6988-96. PubMed ID: 9696790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
    Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
    Moore JP; Cao Y; Qing L; Sattentau QJ; Pyati J; Koduri R; Robinson J; Barbas CF; Burton DR; Ho DD
    J Virol; 1995 Jan; 69(1):101-9. PubMed ID: 7527081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.
    Shi Y; Brandin E; Vincic E; Jansson M; Blaxhult A; Gyllensten K; Moberg L; Broström C; Fenyö EM; Albert J
    J Gen Virol; 2005 Dec; 86(Pt 12):3385-3396. PubMed ID: 16298986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of neutralization sensitivity of HIV-1 primary isolates with biological properties of isolates from HIV-1 infected Chinese individuals.
    Hei FX; Tang HL; Hong KX; Chen JP; Peng H; Yuan L; Xu JQ; Shao YM
    Biomed Environ Sci; 2005 Apr; 18(2):128-36. PubMed ID: 16001833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
    Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
    Martín J; LaBranche CC; González-Scarano F
    J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.
    Cilliers T; Nhlapo J; Coetzer M; Orlovic D; Ketas T; Olson WC; Moore JP; Trkola A; Morris L
    J Virol; 2003 Apr; 77(7):4449-56. PubMed ID: 12634405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
    Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.
    Montefiori DC; Collman RG; Fouts TR; Zhou JY; Bilska M; Hoxie JA; Moore JP; Bolognesi DP
    J Virol; 1998 Mar; 72(3):1886-93. PubMed ID: 9499040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.
    Björndal A; Deng H; Jansson M; Fiore JR; Colognesi C; Karlsson A; Albert J; Scarlatti G; Littman DR; Fenyö EM
    J Virol; 1997 Oct; 71(10):7478-87. PubMed ID: 9311827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
    Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.
    Kozak SL; Platt EJ; Madani N; Ferro FE; Peden K; Kabat D
    J Virol; 1997 Feb; 71(2):873-82. PubMed ID: 8995603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.
    Gorny MK; Mascola JR; Israel ZR; VanCott TC; Williams C; Balfe P; Hioe C; Brodine S; Burda S; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):213-21. PubMed ID: 9491911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.